首页> 美国卫生研究院文献>other >Establishing the role of honest broker: bridging the gap between protecting personal health data and clinical research efficiency
【2h】

Establishing the role of honest broker: bridging the gap between protecting personal health data and clinical research efficiency

机译:建立诚实的经纪人角色:弥合保护个人健康数据和临床研究效率之间的差距

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background. The objective of this study is to propose the four conditions for the roles of honest brokers through a review of literature published by ten institutions that are successfully utilizing honest brokers. Furthermore, the study aims to examine whether the Asan Medical Center’s (AMC) honest brokers satisfy the four conditions, and examine the need to enhance their roles.>Methods. We analyzed the roles, tasks, and types of honest brokers at 10 organizations by reviewing the literature. We also established a Task Force (TF) in our institution for setting the roles and processes of the honest broker system and the honest brokers. The findings of the literature search were compared with the existing systems at AMC—which introduced the honest broker system for the first time in Korea.>Results. Only one organization employed an honest broker for validating anonymized clinical data and monitoring the anonymity verifications of the honest broker system. Six organizations complied with HIPAA privacy regulations, while four organizations did not disclose compliance. By comparing functions with those of the AMC, the following four main characteristics of honest brokers were determined: (1) de-identification of clinical data; (2) independence; (3) checking that the data are used only for purposes approved by the IRB; and (4) provision of de-identified data to researchers. These roles were then compared with those of honest brokers at the AMC.>Discussion. First, guidelines that regulate the definitions, purposes, roles, and requirements for honest brokers are needed, since there are no currently existing regulations. Second, Korean clinical research institutions and national regulatory departments need to reach a consensus on a Korean version of Limited Data Sets (LDS), since there are no lists that describe the use of personal identification information. Lastly, satisfaction surveys on honest brokers by researchers are necessary to improve the quality of honest brokers.
机译:>背景。本研究的目的是通过回顾十家成功利用诚实经纪人的机构发表的文献,为诚实经纪人的角色提出四个条件。此外,该研究旨在检查Asan医疗中心(AMC)的诚实经纪人是否满足这四个条件,并研究增强其角色的必要性。>方法。我们分析了这些角色,任务和类型回顾文献资料,了解10个组织的诚实经纪人。我们还在机构中设立了一个工作组(TF),以设置诚实经纪人系统和诚实经纪人的角色和流程。将文献检索的结果与AMC的现有系统进行了比较,AMC在韩国首次引入了诚实经纪人系统。>结果。。只有一个组织雇用了诚实经纪人来验证匿名临床数据和监视诚实经纪人系统的匿名验证。六个组织遵守了HIPAA隐私法规,而四个组织没有披露合规性。通过将功能与AMC的功能进行比较,确定了诚实经纪人的以下四个主要特征:(1)对临床数据进行身份识别; (2)独立性; (3)检查数据仅用于IRB批准的目的; (4)向研究人员提供身份不明的数据。然后,将这些角色与AMC的诚实经纪人的角色进行比较。>讨论。首先,需要规范诚实经纪人的定义,目的,角色和要求的准则,因为目前尚无法规。其次,韩国的临床研究机构和国家监管部门需要就韩文版的受限数据集(LDS)达成共识,因为没有描述使用个人身份信息的列表。最后,研究人员必须对诚实经纪人进行满意度调查,以提高诚实经纪人的质量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号